Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)

NCT02104817 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02104817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02104817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2014
Completion date
May 27, 2020
Enrollment
13,078 (actual)
Sites
684

Conditions

As the registry lists them; a condition with its own page is linked.

eligible men or women considered high risk for atherosclerotic cardiovascular disease (cvd)